THRomboprophylaxis in Individuals Undergoing Superficial endoVEnous Treatment (THRIVE)

Trial statusRecruiting
Trial phasePhase 4
Trial typeInterventional
Biological sexAll
Age18+
SponsorImperial College London

About this trial

Endovenous interventions are keyhole operations for varicose veins that are carried out from within the vein itself. Varicose veins are enlarged veins close to the surface of the skin. They are connected to the bigger deeper veins in the leg (known as deep veins). Because of this, operations to close the varicose veins can increase the chance of a blood clot forming in the deep veins. Blood clots in the deep veins happen in around 1 in 50 people after endovenous operations. A clot in the leg can cause swelling, pain, and other long-term problems. If a clot in the leg breaks off and travels to the lungs, it can cause problems with the lung' ability to move oxygen from the air into the blood and may, in rare cases, be life threatening.

Varicose vein procedures may carry a slightly higher risk of blood clot formation, and we are currently unsure if current clot reducing medicines are beneficial in preventing blood clots in people having varicose vein procedures.

This study will investigate if it is worthwhile prescribing medicines to reduce blood clots after varicose vein procedures.

Eligibility criteria

Qualifiers

Adults (>18 years)

Scheduled to undergo endovenous intervention of truncal varicose veins under local anaesthesia

Treatment technologies including radiofrequency, laser, mechanochemical, foam sclerotherapy and cyanoacrylate glue

Disqualifiers

Clinical indication for therapeutic anticoagulation e.g., atrial fibrillation

Previous personal or first-degree relative history of VTE

Thrombophilia

Female patients of childbearing potential who have a positive pregnancy test

Trial design

Treatments tested in this trial

  • Dalteparin Sodium
  • Tinzaparin Sodium
  • Enoxaparin Sodium
  • Rivaroxaban
  • Apixaban
  • Dabigatran Etexilate

Treatment groups

3,175 Participants
are divided into 3 treatment groups

Sponsors and collaborators